26 June 2023
14 May 2023
14 May 2023
-
14 November 2023
-
14 November 2023
Results from Ipsen’s ELATIVE® pivotal Phase III trial of elafibranor in PBC presented as late breaking data at AASLD congress and published in New England Journal of Medicine
PARIS, FRANCE, 13 November, 2023 – Ipsen (Euronext: IPN; ADR: IPSEY) and GENFIT (Nasdaq and Euronext: GNFT) today announced full results from the pivotal Phase III ELATIVE® trial, which are being presented in a late-breaking oral session (Abstract #484,...
-
10 May 2024
-
10 May 2024
-
10 May 2024
- 3 mins read
-
10 May 2024
- 3 mins read
Seven Years Out: The road to recovery from a stroke-like episode
Randy loves to read, enjoy the outdoors, and spend time with his family. He enjoys going to the gym and took up aquatic therapy to exercise and make new friends. He’s come a long way since he experienced a car accident, which led to traumatic brain injur...
-
29 February 2024
- 4 mins read
-
29 February 2024
- 4 mins read
Shared decision-making: A true patient-centric approach to care
Monia Vial, Senior Vice President, Franchise Head, Rare Disease Business Unit at Ipsen reflects on a conversation with Courageous Parents Network to educate Ipsen colleagues about shared decision-making and potential positive impacts when we better underst...
-
05 June 2023
-
05 June 2023
-
13 June 2023
-
13 June 2023
U.S. FDA approves Bylvay® for patients living with cholestatic pruritus due to Alagille syndrome
PARIS, FRANCE, 13 June 2023 – Ipsen (Euronext: IPN: ADR: IPSEY) today announced that the U.S. Food and Drug Administration (FDA) has approved Bylvay® (odevixibat) for the treatment of cholestatic pruritus in patients from 12 mon...